CSIMarket
 
Mesa Laboratories Inc  (NASDAQ: MLAB)
    Sector  Technology    Industry IT Infrastructure
   Industry IT Infrastructure
   Sector  Technology
 
Price: $127.7800 $-0.75 -0.584%
Day's High: $128.2899932861328 Week Perf: -0.07 %
Day's Low: $ 125.59 30 Day Perf: 26.5 %
Volume (M): 100,553 52 Wk High: $ 132.70
Volume (M$): $ 0 52 Wk Avg: $89.88
Open: $126.09 52 Wk Low: $58.83



 Market Capitalization (Millions $) 736
 Shares Outstanding (Millions) 6
 Employees 717
 Revenues (TTM) (Millions $) 249
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 3

Business Description


Mesa Laboratories, Inc. was incorporated under the laws of the State of Colorado on March 26, 1982. We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into three divisions across six physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments.

Our Lakewood, Colorado, and Butler, New Jersey, facilities manufacture our Instruments Division products which include the DataTrace®, DialyGuard®, DryCal®, Torqo®, SureTorque® and BGI brands. Our Omaha, Nebraska, and Bozeman, Montana locations manufacture our Biological Indicators Division products which include the Mesa, PCD® and Apex® brands, while our Lakewood, Colorado, facility also manufactures our Continuous Monitoring Division products which include CheckPoint® and AmegaView brands.

Our philosophy is to manufacture exceptional quality products and provide a high level of on-going service for those products. Our revenues come from two main sources – product sales and services. Our strategic goals involve continuing to grow revenues and profits through three key strategies – a) improving our distribution channels, b) introducing new products to the market, and c) seeking out companies or product lines to acquire.

Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products and acquisitions. Biological indicator products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products and continuous monitoring systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products and continuous monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we try to pass along cost increases in order to maintain our margins.



   Company Address: 12100 West Sixth Avenue Lakewood 80228 CO
   Company Phone Number: 987-8000   Stock Exchange / Ticker: NASDAQ MLAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Mesa Laboratories (MLAB) Declares Quarterly Dividend of $0.16, Reflecting Strong Financial Commitment,

Published Mon, Apr 7 2025 7:35 PM UTC

Mesa Laboratories Declares Quarterly Dividend, Reflects Commitment to Shareholder Value LAKEWOOD, Colo. April 7, 2025 Mesa Laboratories, Inc. (NASDAQ: MLAB) has announced its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. This dividend is set to be paid on June 16, 2025, to shareholders who are on record as of the close o...

Announcement

Mesa Laboratories, Inc. Demonstrates Financial Strength with Declaration of Quarterly Dividend

Published Mon, Jul 8 2024 6:00 PM UTC

Mesa Laboratories, Inc. recently made an exciting announcement, declaring a regular quarterly dividend of $0.16 per share for its common stock. This news reflects the company s commitment to providing value to its shareholders and its confidence in its financial performance.The dividend payout is set to be made on September 16, 2024, to the shareholders of record as of Augus...

Announcement

Mesa Laboratories Commitment to Financial Accuracy: Audit Delay Reflects Companys Int...

Published Fri, May 31 2024 10:00 AM UTC

Mesa Laboratories, Inc. (Mesa) (NASDAQ:MLAB), a leading global provider of quality control solutions, has announced a delay in the release of its unaudited fourth-quarter and full fiscal year 2024 financial results. The delay is due to ongoing efforts by the company to finalize its year-end audit, which is primarily focused on completing the calculations and technical accoun...

Announcement

Mesa Laboratories, Inc. Postpones Earnings Announcement and Highlights Commitment to Responsible Business Practices in New ESG Program Brochure

Published Wed, May 22 2024 10:00 AM UTC

Mesa Laboratories, Inc. Revises Earnings Announcement and Releases Second Annual Responsible Business Program BrochureMesa Laboratories, Inc., a global leader in life science tools and critical quality control solutions, has recently announced two significant updates. The company has revised the earnings announcement date for its unaudited fourth quarter and full fiscal year...

Announcement

Mesa Laboratories, Inc. Set to Reveal Financial Results, Bringing Transparency and Insight to its Fourth Quarter and Full Fiscal Year 2024 Performance

Published Mon, Apr 1 2024 2:27 PM UTC

Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024LAKEWOOD, Colo., April 01, 2024 - Mesa Laboratories, Inc., a leading global provider of critical quality control solutions for various industries, including pharmaceuticals, medical devices, and food and beverage, has announced that it will be releasing its financial...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 150.33
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.95
Price to Sales (Expected) -
Price to Book 3.9
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.56
Working Capital Ratio 1.82
Leverage Ratio (MRQ) 1.22
Total Debt to Equity 0.38
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.37

Per Share Current
Earnings (TTM) 0.85 $
Revenues (TTM) 43.33 $
Cash Flow (TTM) 0.98 $
Cash 5.6 $
Book Value 32.79 $
Dividend (TTM) 0.64 $

Efficiency Current
Revenue per Employee (TTM) 347,934
Net Income per Employee (TTM) 6,695
Receivable Turnover Ratio (TTM) 6.21
Inventory Turnover Ratio (TTM) 3.34
Asset Turnover Ratio (TTM) 0.58

Profitability Ratios Current
Gross Margin (MRQ) 64.87 %
Operating Margin (MRQ) 11.69 %
Net Margin (MRQ) 4.71 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 48.69 %

Management Effectiveness Current
Return On Assets (TTM) 1.12 %
Return On Investment (TTM) 1.39 %
Return On Equity (TTM) 2.69 %
Dividend Yield 0.5 %
Pay out Ratio (TTM) 75.29 %



Mesa Laboratories Inc's Segments
Sterilization and Disinfection Control    40.75 % of total Revenue
Biopharmaceutical Development    20.05 % of total Revenue
Calibration Solutions    22.09 % of total Revenue
Clinical Genomics    17.11 % of total Revenue
Consumables    57.83 % of total Revenue
Hardware and Software    23.49 % of total Revenue
Service    18.68 % of total Revenue
US    49.46 % of total Revenue
CN    9.04 % of total Revenue
Other    41.5 % of total Revenue
Corporate Non Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.